Related Experiment Video
Updated: May 12, 2026
15:17
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
14.3K
Expression and Clinical Significance of CD47 in Colorectal Cancer: A Review
Qijie Li1, Paola Vignali2, Donghao Tang2
1Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy.
Cancers
|January 10, 2026
Summary
Cluster of Differentiation 47 (CD47) is overexpressed in colorectal cancer (CRC), aiding immune evasion. Standardized evaluation is crucial for its use as a biomarker and therapeutic target in CRC.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Cluster of Differentiation 47 (CD47) is an innate immune checkpoint protein.
- CD47 binding to signal regulatory protein alpha (SIRPα) inhibits macrophage phagocytosis, facilitating tumor immune escape.
- CD47's role in colorectal cancer (CRC) is an area of increasing research interest.
Purpose of the Study:
- To review and synthesize findings on CD47 expression and significance in colorectal cancer (CRC).
- To assess CD47 as a potential biomarker and therapeutic target in CRC.
Main Methods:
- Review of five immunohistochemistry (IHC) studies on CD47 in CRC.
- Analysis of complementary transcriptomic data for CD47 in CRC.
- Correlation analysis of CD47 levels with clinical parameters and immune infiltration.
Main Results:
- Consistent membrane overexpression of CD47 in CRC tissues observed via IHC, with variable positivity rates (16-91%) due to methodological differences.
- Transcriptomic analyses confirmed CD47 upregulation, particularly in Consensus Molecular Subtype 1 (CMS1) and CMS4 CRC subtypes.
- High CD47 expression correlated with advanced TNM stage, metastasis, poor differentiation, and altered immune infiltration, though prognostic impact varied.
Conclusions:
- CD47 is frequently overexpressed in CRC and associated with aggressive clinicopathological features.
- CD47 shows potential as a prognostic biomarker and therapeutic target in CRC.
- Standardized methodologies, including antibody selection and scoring criteria, are essential for clinical translation of CD47 evaluation.
